Hepatology News and Research

RSS

Hepatology is the branch of medicine that incorporates study of liver, gallbladder, biliary tree and pancreas as well as management of their disorders.

Nanobac announces Baylor initial results for nanoparticle and gall stone formation study

Nanobac Pharmaceuticals Inc has announced that scientists at the Baylor College of Medicine, working under a collaborative agreement with Nanobac, have cited evidence showing the presence of calcifying nanoparticles (CNPs) in surgically resected gallbladders with cholelithiasis (Gall Stones).

15 Jan 2008

Review of transplant issues in patients with biliary atresia

The most common indication worldwide for pediatric transplantation, biliary atresia is also the most common cause of chronic liver disease in newborns.

9 Jan 2008

New biomarker for predicting liver cancer spread and survival discovered

New research has shown that a unique pattern of microRNAs, small RNA molecules that regulate gene activity, can accurately predict whether liver cancer will spread and whether liver cancer patients will have shorter or longer survival, even patients with early stage disease.

7 Jan 2008

Shorter HCV treatment shows notable success

Two new randomized controlled trials show that treating Hepatitis C (HCV) with peginterferon and ribavirin for shorter durations can yield success rates similar to those from longer treatment lengths, with cost-savings and lower risk of serious side effects.

3 Jan 2008

MRI techniques evolving towards better assessment of liver fibrosis

MRI imagery is emerging as a non-invasive way to determine the existence and extent of hepatic fibrosis.

3 Jan 2008

Hereditary form of colon cancer traced to common ancester in U.S.

A married couple who sailed from England to America around 1630 may be the ancestors of hundreds of people alive today who are at risk for a hereditary form of colon cancer.

3 Jan 2008

Drug effective for hepatitis C patients with low platelets

For patients with hepatitis C, having a low blood platelet count is a frequent complication associated with advanced disease.

2 Jan 2008

Optimal therapy for U.S. hepatitis C patients

As reported recently in the journal Hepatology, WIN-R, a multicenter study of over 5,000 patients with hepatitis C virus (HCV) showed treatment with weight-based REBETOL ribavirin, USP) (RBV) in combination with pegylated interferon (PEG-IFN) alfa-2b achieved significantly higher rates of sustained virologic response (SVR) and lower relapse rates compared to combination therapy using a flat dose of RBV 800 mg/day. Superior response was found particularly in patients with the most difficult-to-treat form of the disease, genotype 1 HCV. Efficacy was consistent across all weight groups.

28 Dec 2007

Greater need for education regarding blood borne viruses

A new cohort study could facilitate targeted interventions for adolescent offenders who are at a high risk of hepatitis C (HCV) infection and obesity related liver disease.

10 Dec 2007

Treating patients with psychiatric disorders for hepatitis C

People with severe mental illnesses are far more likely to be infected with Hepatitis C virus compared to the general population, however, they often do not get treatment for their liver disease because current antiviral therapies have known psychiatric side effects.

4 Dec 2007

New upper limit defined for normal ALT in adolescent males

A new cohort study of adolescent offenders in Australia has identified an upper limit for alanine aminotransferase (ALT) that is more sensitive for the diagnosis of liver disease.

4 Dec 2007

Compound of milk thistle shows anti-cancer effects

Recently, scientists demonstrated the anti-cancer effects of silibinin, a major biologically active compound of milk thistle. Being widely used as a folk remedy for liver diseases, milk thistle is safe and well-tolerated, and it protects the liver from drug or alcohol-related injury.

15 Nov 2007

Minority patients do not necessarily have worse outcomes after liver transplantation

When treated at the same medical centers as Caucasians, they fare just as well. These are the results of a new study in the November issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience.

2 Nov 2007

High-fat diet makes mice susceptible to liver injury

A high fat diet may kill regulatory T cells in the liver, allowing steatosis (simple fatty liver) to develop into steatohepatitis (fatty liver with inflammation), according to the results of a new study in the November issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).

2 Nov 2007

Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C

Patients with hepatitis C treated with combination therapy of pegylated interferon and ribavirin had better outcomes when taking a weight-based dosage of ribavirin compared to a flat dosage.

2 Oct 2007

Noninvasive tests for cirrhosis may help to avoid liver biopsy

Newer ultrasound and magnetic resonance (MR) imaging tests yield encouraging initial results in diagnosing fibrosis (scarring) and cirrhosis of the liver, according to three studies in the October issue of the journal Clinical Gastroenterology and Hepatology.

2 Oct 2007

Rapamycin and Gleevec reverses effects of portal hypertension in rats

A combined treatment with rapamycin and Gleevec might reverse the effects of portal hypertension in patients with chronic liver disease, according to the results of a new study on rats.

2 Oct 2007

Common abdominal pain may be due to a potentially treatable newly recognized inflammatory reaction

As many as one in four people in westernized countries experience pain or discomfort in their upper abdomen, and physicians have almost nothing to offer except anti-acid medicines, which usually don't work.

20 Sep 2007

First-degree relatives of patients with primary biliary cirrhosis more likely to have biomarkers of the disease

Armed with this new information, physicians could screen and assess first-degree relatives of PBC patients with a simple blood test, enabling them to diagnose and treat more patients before the disease causes irreversible liver damage. These findings were published in this month's issue of Hepatology.

11 Sep 2007

Case report on a shining significance in living donor transplantation

Touching stories of living donor transplantation are continuously happening in hospitals.

30 Aug 2007

Hepatology News and Research

Further Reading

Nanobac announces Baylor initial results for nanoparticle and gall stone formation study

Review of transplant issues in patients with biliary atresia

New biomarker for predicting liver cancer spread and survival discovered

Shorter HCV treatment shows notable success

MRI techniques evolving towards better assessment of liver fibrosis

Hereditary form of colon cancer traced to common ancester in U.S.

Drug effective for hepatitis C patients with low platelets

Optimal therapy for U.S. hepatitis C patients

Greater need for education regarding blood borne viruses

Treating patients with psychiatric disorders for hepatitis C

New upper limit defined for normal ALT in adolescent males

Compound of milk thistle shows anti-cancer effects

Minority patients do not necessarily have worse outcomes after liver transplantation

High-fat diet makes mice susceptible to liver injury

Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C

Noninvasive tests for cirrhosis may help to avoid liver biopsy

Rapamycin and Gleevec reverses effects of portal hypertension in rats

Common abdominal pain may be due to a potentially treatable newly recognized inflammatory reaction

First-degree relatives of patients with primary biliary cirrhosis more likely to have biomarkers of the disease

Case report on a shining significance in living donor transplantation

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News